ABSTRACT
The clinical potential of tumor therapies must be evaluated using animal models closely resembling human cancers. We investigated the impact of locally delivered interferon-gamma (IFN-gamma) on primary hepatocarcinoma spontaneously developed by T-SV40 transgenic mice. A single intratumor injection of adenovirus IFN-gamma was sufficient enough to induce in vivo production of biologically active IFN-gamma, as assessed by STAT1 activation. IFN-gamma secretion led to the regression of primary tumor, principally by apoptosis of tumor hepatocytes. The lack of T-cells infiltrates in the liver upon treatment excluded a role of a specific immune response. In contrast, indirect pathways may include tumoricidal function of macrophages. Indeed, they were massively recruited in the entire liver under IFN-gamma treatment; transmigration through hepatic blood vessels could be observed and co-localization with damaged hepatocytes was obvious. This correlated with nonparenchymal liver cell iNOS expression and high level of NO in hepatic extracts. Moreover, in vitro experiments showed that NO releasing agents induced cell death of freshly isolated tumor hepatocytes, suggesting that NO could be one of the major effector molecules. Altogether, these observations defined an important role of IFN-gamma in controlling tumor development in a model of primary hepatocarcinoma.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/therapy , DNA-Binding Proteins/metabolism , Genetic Therapy/methods , Interferon-gamma/genetics , Liver Neoplasms/therapy , Macrophages/immunology , Nitric Oxide Synthase/biosynthesis , Nitric Oxide/biosynthesis , Trans-Activators/metabolism , Adenoviridae/genetics , Adenoviridae/metabolism , Animals , Apoptosis/genetics , DNA-Binding Proteins/genetics , Enzyme-Linked Immunosorbent Assay , Genetic Vectors , Image Processing, Computer-Assisted , Immunohistochemistry , Mice , Mice, Transgenic , Nitric Oxide Synthase Type II , STAT1 Transcription Factor , Simian virus 40/genetics , Trans-Activators/genetics , Transcriptional Activation , Transduction, GeneticABSTRACT
Efficient and homogeneous gene transfer to cardiac myocytes is a major target in myocardial gene therapy. The aim of this study was to determine the conditions permitting efficient, homogeneous, adenovirus-mediated gene transfer to cardiac myocytes, with a view to application during coronary artery catheterization. Gene transfer to adult rat ventricular myocytes was conducted using type 5 adenoviruses carrying the lacZ reporter gene. Adenovirus delivery via coronary arteries was performed on isolated perfused rat hearts, and gene transfer efficiency was analyzed on whole ventricles, freshly isolated myocytes, and cultured myocytes. Single-pass delivery of 1 X 10(9) PFU associated with 1 min of no-flow yielded only 1 +/- 0.5% of positive myocytes. Pretreatment by histamine perfusion (10(-5) M final concentration) increased this value to 30 +/- 9% (p < 0.001), and pretreatment by Ca2+-free buffer perfusion increased it to 67 +/- 8% (p < 0.001). Combination of the two pretreatments had no additional effect. Increasing the viral dose to 3 X 10(9) PFU increased transfection efficiency only in permeabilized vessels. The 1-min no-flow period after adenovirus delivery was crucial for efficient gene transfer: despite histamine pretreatment, only 2 +/- 1% positive myocytes were observed without flow interruption (p < 0.05 versus 1 min of no-flow). Gene transfer was shown to occur in situ during cardiac perfusion, rather than during heart digestion or myocyte isolation. This study shows that highly efficient adenovirus-mediated gene transfer to cardiac myocytes in situ can be achieved by single-pass intracoronary vector delivery, provided that vascular permeability is first increased and coronary flow is briefly interrupted.
Subject(s)
Adenoviridae/genetics , Coronary Vessels , Gene Transfer Techniques , Genetic Vectors/administration & dosage , Heart/virology , Myocardium/cytology , Animals , Buffers , Calcium/metabolism , Cardiomyopathies/chemically induced , Coronary Circulation , Edema/chemically induced , Heart/drug effects , Hemodynamics , Histamine/pharmacology , In Vitro Techniques , Male , Nitroprusside/pharmacology , Norepinephrine/pharmacology , Rats , Rats, Wistar , Vasodilation/drug effects , Vasodilator Agents/pharmacologyABSTRACT
In vivo transfer of wild-type (wt) p53 gene via a recombinant adenovirus has been proposed to induce apoptosis and increase radiosensitivity in several human carcinoma models. In the context of combining p53 gene transfer and irradiation, we investigated the consequences of adenoviral-mediated wtp53 gene transfer on the cell cycle and radiosensitivity of a human head and neck squamous cell carcinoma line (SCC97) with a p53 mutated phenotype. We showed that ectopic expression of wtp53 in SCC97 cells resulted in a prolonged G1 arrest, associated with an increased expression of the cyclin-dependent kinase inhibitor WAF1/p21 target gene. A transient arrest in G2 but not in G1 was observed after irradiation. This G2 arrest was permanent when exponentially growing cells were transduced by Ad5CMV-p53 (RPR/INGN201) immediately after irradiation with 5 or 10 Gy. Moreover, levels of cyclins A2 and B1, which are known to regulate the G2/M transition, dramatically decreased as cells arrived in G2, whereas maximal levels of expression were observed in the absence of wtp53. In conclusion, adenoviral mediated transfer of wtp53 in irradiated SCC97 cells, which are mutated for p53, appeared to increase WAF1/p21 expression and decrease levels of the mitotic cyclins A2 and B1. These observations suggest that the G2 arrest resulted from a p53-dependent premature inactivation of the mitosis promoting factor.
Subject(s)
Carcinoma, Squamous Cell/pathology , Cyclin A/metabolism , Cyclin B/metabolism , G2 Phase/physiology , Head and Neck Neoplasms/pathology , Tumor Suppressor Protein p53/physiology , Adenoviridae/genetics , Apoptosis/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/metabolism , Cyclin A2 , Cyclin B1 , G2 Phase/radiation effects , Gene Transfer Techniques , Genes, p53 , Genetic Vectors , Head and Neck Neoplasms/genetics , Head and Neck Neoplasms/metabolism , Humans , Phenotype , RNA, Messenger/genetics , Tumor Cells, CulturedABSTRACT
We have shown that the loss of p53 function contributed to resistance of tumor cells to TNF-induced cytotoxicity. In the present study, we evaluated the effect of wild-type p53 (wt-p53) expression on TNF sensitivity, by introducing wt-p53 into MCF7/Adr cells in which p53 was deleted, via a recombinant adenovirus encoding p53 (Ad-p53). Our results indicate that infection with Ad-p53 (50-100 viral particles per cell) resulted in pronounced cytotoxicity, whereas infection with 10 viral particles per cell, which was weakly toxic for the MCF7/Adr cells, sensitized these cells to TNF-induced cell death. Moreover, expression of wt-p53 in MCF7/Adr cells induced the production of reactive oxygen intermediates (ROIs) and caused glutathione (GSH) depletion, indicating disturbances in the cellular redox state. Additional treatment of cells with the anti-oxidant and glutathione (GSH) precursor N-acetylcysteine (NAC) resulted in inhibition of p53-induced ROIs production and in partial restoration of intracellular GSH levels, which was associated with the ability of NAC to inhibit p53-modulated TNF-induced cytotoxicity. Interestingly, Ad-p53 was able to inhibit TNF-induced MnSOD mRNA expression in MCF7/Adr cells, which might contribute to the sensitization of cells to the cytotoxic action of TNF. Taken together, our data strongly suggest that wt-p53 expression sensitizes TNF-resistant MCF7 cells with p53 deletion to TNF-induced cell death by a pathway that is dependent on ROIs production.
Subject(s)
Adenoviridae/genetics , Gene Expression/drug effects , Genetic Vectors/pharmacology , Tumor Necrosis Factor-alpha/pharmacology , Tumor Suppressor Protein p53/genetics , Acetylcysteine/pharmacology , Breast Neoplasms/enzymology , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Breast Neoplasms/virology , Cytopathogenic Effect, Viral , Down-Regulation/drug effects , Drug Resistance, Neoplasm/genetics , Female , Genetic Vectors/genetics , Humans , Oxidation-Reduction , Oxidative Stress/drug effects , Oxidative Stress/genetics , RNA, Messenger/biosynthesis , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism , Transfection , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Suppressor Protein p53/antagonists & inhibitors , Tumor Suppressor Protein p53/biosynthesisABSTRACT
Tumor suppressor p53 is a nuclear transcription factor that blocks cell cycle progression and induces apoptosis. We have previously shown that the MCF7 resistance to the cytotoxic action of TNF correlates with p53 mutations. In the present study, we used a recombinant adenovirus carrying a wild-type p53 gene (Adwtp53) in order to investigate the effect of wt p53 transfer on modulation of cell resistance to the cytotoxic action of TNF. Our data indicate that infection of TNF resistant MCF7 cells (1001 and MCF7/Adr) with Adwtp53 resulted in the restoration of wt p53 expression and function as respectively revealed by the yeast assay and the induction of p53 inducible genes MDM2 and p21. Furthermore, the restoration of p53 function significantly sensitized TNF resistant cells to TNF cytotoxic action. This correlated with a significant down-regulation of c-myc in both TNF-resistant cell lines and a decrease of Retinoblastoma protein (Rb) in 1001 clone. In contrast, the effect of p53 seems to be independent from Bcl-2 and Bax protein level regulation. The present study suggests that the combination of TNF and Adwtp53 may be a potential strategy to sensitize mutant p53 TNF-resistant tumors to the cytotoxic action of this cytokine.
Subject(s)
Adenoviridae/genetics , Antineoplastic Agents/pharmacology , Nuclear Proteins , Proto-Oncogene Proteins c-myc/metabolism , Retinoblastoma Protein/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Tumor Suppressor Protein p53/physiology , Cell Division/drug effects , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/biosynthesis , Down-Regulation , Drug Resistance, Neoplasm , Gene Transfer Techniques , Humans , Proto-Oncogene Proteins/biosynthesis , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-mdm2 , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics , bcl-2-Associated X ProteinABSTRACT
Cancer immunotherapy often aims at the reactivation and expansion of tumor-specific CTL. In an attempt to correlate in situ and/or systemic tumor-specific T cell expansion with tumor regression, we investigated the effects of adenovirus-mediated IL-12 or IFN-gamma gene transfer into established P815 murine tumors. While IFN-gamma was no more potent than the vector alone, IL-12 gene transfer promoted tumor eradication. Despite this antitumor effect, no significant cytolytic activity was detectable using classical cytotoxicity assays from in vitro restimulated splenocytes. Since intratumor gene delivery may induce a localized expansion of CTL, the presence of P815-specific CD8+ T cells in situ was assessed. Using the Immunoscope approach, we found a dramatic increase in clonotypic T cells at the tumor site following IL-12, but not IFN-gamma gene delivery. Antitumor CD8+ T cell frequencies were then re-evaluated using this molecular detection technique, which revealed a comparable expansion of specific T cells in the peripheral organs, most strikingly in the blood. These data show that local IL-12 gene transfer, in contrast to IFN-gamma, mediates a potent antitumor effect that correlates to clonal tumor-specific T cell expansions in situ and in the periphery.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Epitopes, T-Lymphocyte/blood , Genetic Therapy , Interleukin-12/genetics , Mast-Cell Sarcoma/therapy , Sarcoma, Experimental/therapy , T-Lymphocyte Subsets/immunology , Adenoviridae/genetics , Animals , CD8-Positive T-Lymphocytes/metabolism , Cell Movement/genetics , Cell Movement/immunology , Cytotoxicity, Immunologic/genetics , Female , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Genetic Vectors/therapeutic use , Injections, Intravenous , Interferon-gamma/biosynthesis , Interleukin-12/metabolism , Interleukin-12/therapeutic use , Lymphocyte Count , Mast-Cell Sarcoma/blood , Mast-Cell Sarcoma/genetics , Mast-Cell Sarcoma/immunology , Mice , Mice, Inbred DBA , Recombination, Genetic , Sarcoma, Experimental/blood , Sarcoma, Experimental/genetics , Sarcoma, Experimental/immunology , T-Lymphocyte Subsets/metabolism , Time FactorsABSTRACT
Adenoviral vectors have the potential to infect a large number of cell types including quiescent cells. Their use in hematopoietic cells is limited by the episomal form of their DNA, leading to transgene loss in the progeny cells. However, the use of this vector may be interesting for short-term in vitro modifications of primitive human hematopoietic cells. Therefore, we have investigated the ability of adenovirus to transduce cord blood CD34+ cells. Several promoters were tested using the lacZ reporter gene. The PGK and CMV promoters induced transgene expression in 18-25% of the cells, whereas the HTLV-I and especially the RSV promoter were almost inactive. To improve infection efficiency, adenovirus was complexed with cationic lipids. Lipofectamine, Cellfectin, and RPR120535b, but not Lipofectin, Lipofectace, or DOTAP, markedly improved transgene expression in CD34+ cells (from 19 to 35%). Lipofectamine strongly enhanced infection efficiency of the poorly infectable primitive CD34+CD38low cells (from 11 to 28%) whereas the more mature CD34+CD38+ cells were only slightly affected (from 24 to 31%). Lipofectamine tripled the infection of CFU-GMs and LTC-ICs derived from the CD34+CD38low cell fraction (from 4 to 12% and from 5 to 16%, respectively) and doubled that of BFU-Es (from 13 to 26%). We conclude that cationic lipids can markedly increase the efficiency of adenovirus-mediated gene transfer into primitive hematopoietic cells.
Subject(s)
Adenoviridae/genetics , Antigens, CD , Cation Exchange Resins/pharmacology , Genetic Vectors , Hematopoietic Stem Cells/metabolism , Lipids/pharmacology , ADP-ribosyl Cyclase , ADP-ribosyl Cyclase 1 , Antigens, CD34/immunology , Antigens, Differentiation/immunology , Cations , Genes, Reporter , Hematopoietic Stem Cells/immunology , Humans , Lac Operon , Membrane Glycoproteins , NAD+ Nucleosidase/immunology , Phenotype , Promoter Regions, GeneticABSTRACT
The use of gene-modified tumor cells as a strategy for active immunotherapy is currently undergoing intensive fundamental and clinical research. Most clinical trials use gamma-ray-irradiated tumor cells as vaccine, although little is known about the effects of irradiation on the immunogenicity of tumor cells. In particular, no data have been reported so far concerning the effects of gamma-ray irradiation on the expression of B7 molecules in tumor cells. In this paper, we show a neoexpression of the B7.1 molecule after gamma-ray irradiation in tumor cell lines from different tissues, while the B7.2 molecule remains unexpressed in all the cell lines tested. Furthermore, the induction of B7.1 molecule membrane expression after irradiation is shown to result from the neoexpression of B7.1 mRNA, and to be reproduced with H2O2 oxidative stress. These data could explain the enhanced immunogenicity of many tumor cells after irradiation, and could lead to new immunotherapy protocols.
Subject(s)
B7-1 Antigen/biosynthesis , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/radiotherapy , Animals , Gamma Rays , Liver Neoplasms, Experimental/immunology , Liver Neoplasms, Experimental/metabolism , Liver Neoplasms, Experimental/radiotherapy , Mice , Mice, Transgenic , Neoplasms, Experimental/immunology , Tumor Cells, Cultured/radiation effectsABSTRACT
Adenoviral vectors may be useful tools to deliver a cytokine in vivo. A single intravenous injection of an adenovirus vector containing the human thrombopoietin (TPO) cDNA (AdRSVhuTPO) was able to induce a thrombocytosis for more than 6 weeks in SCID mice, associated with a megakaryocyte (MK) hyperplasia in different organs. A marrow and spleen fibrosis was observed at 6 weeks. In immunocompetent mice, a single AdRSVhuTPO injection led to a moderate and transient thrombocytosis without myelofibrosis. To evaluate the usefulness of TPO for the prevention of secondary side-effects during an aplastic period, mice were subjected to a myeloablative regimen 7 days after the intravenous AdRSVhuTPO injection. In this setting, TPO prevented mortality by accelerating hematological recovery. Survival was essentially related to an improvement in the leukopenia since all control mice died from septicemia. However, the effects of TPO may be potentiated by the release of inflammatory cytokines following the adenovirus infection; AdRSV beta galactosidase injected-mice had higher numbers of BFU-E and CFU-GM in the marrow than PBS-injected mice. Myelosuppression induced transient immunosuppression responsible for a sustained expression and elevation of platelet numbers for at least 5 months. These results further suggest that TPO may be an effective therapy in diminishing hematological complications related to myeloablative regimens, but emphasize that immunosuppression secondary to myelosuppression may lead to sustained expression associated with a risk of thrombosis and myelofibrosis when delivered by adenovirus vectors.
Subject(s)
Adenoviridae , Anemia/prevention & control , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Immunosuppression Therapy/adverse effects , Sepsis/prevention & control , Thrombopoietin/genetics , Animals , Bone Marrow/pathology , Gene Expression , Liver/pathology , Mice , Mice, SCID , Platelet Count , Primary Myelofibrosis/etiology , Primary Myelofibrosis/pathology , Spleen/pathology , Time FactorsABSTRACT
Adenovirus vectors have emerged as potent agents for gene transfer. Immune response against the vector and the encoded protein is one of the major factors in the transient expression following in vivo gene transfer. A single injection of an adenovirus encoding human thrombopoietin (TPO) into mice induced transient thrombocytosis, followed by a chronic immune thrombocytopenia. Thrombocytopenic mice had anti-human TPO Abs of the IgG2a and IgG1 isotypes. Thrombocytopenic mice sera neutralized more efficiently human than murine TPO, and exhibited no detectable anti-murine TPO Abs. Despite their low affinity for murine TPO, anti-TPO Abs induced a TPO knockout-like phenotype, i.e., low number of marrow megakaryocytes and of all kinds of hemopoietic progenitors. Hybridomas derived from a thrombocytopenic mouse revealed cross-reactivity of all of the secreted anti-TPO Ab isotypes. Mice subjected to myelosuppression after virus injection showed that anti-human TPO of IgG1 and IgG2a isotypes disappeared. Thus, sustained human TPO production was responsible for platelet elevation for at least 5 mo. Compelling results showed that elevated IgG2a/IgG2b ratios are always associated with thrombocytopenia, whereas low ratios are associated with tolerance or normal platelet counts. Finally, we hypothesize that in humans some chronic thrombocytopenia associated with a low TPO plasma level are due to anti-TPO Abs.
Subject(s)
Adenoviridae/immunology , Antibodies/immunology , Gene Transfer Techniques , Genetic Vectors/immunology , Thrombopoietin/immunology , Animals , Antibody Specificity , Cross Reactions , Humans , Mice , Recombinant Proteins/immunology , Thrombocytopenia/immunologyABSTRACT
The use of genetically modified tumor cells as vaccines has been successful in numerous animal models of grafted syngenic tumors and has provided the groundwork for many clinical trials of gene therapy in cancer patients. To investigate the real efficacy of ex vivo gene therapy-based vaccines, we used transgenic mice that express the SV40 large T and small t antigens under the control of hepatic antithrombin III (ASV-B)-regulatory sequences. These mice systematically develop hepatocarcinoma. Hepatoma cells, derived from ASV-B transgenic mice, were gene-transduced to express either interleukin-2, interleukin-4, the granulocyte-macrophage colony-stimulating factor, or the T-cell costimulatory molecule B7.1. First, we demonstrated the vaccine potential of engineered hepatoma cells by immunizing nontransgenic mice with these cells, which prevented the growth of subsequent grafted nontransduced hepatoma cells. However, vaccination of pretumoral transgenic animals with various combinations of engineered hepatoma cells failed to inhibit hepatoma onset and progression. Rather, tumor development in ASV-B mice appears to be dependent on the immune system, since neonatal induction of immunotolerance to tumor in ASV-B mice cells was associated with a moderate, but significant, acceleration of tumor development. These results seriously call into question the efficacy of this strategy of active vaccinotherapy against natural tumors.
Subject(s)
Cancer Vaccines/therapeutic use , Neoplasms, Experimental/prevention & control , Transduction, Genetic , Animals , Antigens, Polyomavirus Transforming/genetics , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neoplasms, Experimental/geneticsABSTRACT
Regression of P815 tumors established on naive syngeneic mice can be obtained by the intratumoral injection of a single dose of an adenoviral vector expressing the IL-2 gene (Ad.IL2). Injection triggers local IL-2 production for at least 10 days. We measured a number of immunologic parameters in situ following intratumoral Ad.IL2 treatment. We also analyzed the situation of regression obtained upon challenge with P815 cells of mice previously immunized against the tumor and compared both systems. While IFN-gamma messenger RNA expression was found to be elevated in both situations of tumor regression, the level of infiltration by tumor-specific CTL was different. A small amount of tumor-specific CD8+ T cells were present in growing, untreated tumors. Such cells are found in much larger numbers in tumors rejected upon challenge, consistent with a CTL-mediated rejection. In contrast, they were found not to proliferate following Ad.IL2 injection. The latter caused an increased infiltration of a polyclonal, presumably nonspecific, T cell population. These results suggest that the initial regression of established P815 tumors following Ad.IL2 treatment in vivo is mostly due to nonspecific effectors.
Subject(s)
Gene Transfer Techniques , Interleukin-2/genetics , Lymphocyte Activation/genetics , Mast-Cell Sarcoma/immunology , Mast-Cell Sarcoma/therapy , T-Lymphocytes, Cytotoxic/immunology , Animals , Female , Graft Rejection/genetics , Graft Rejection/immunology , Interferon-gamma/biosynthesis , Interferon-gamma/genetics , Interleukin-2/administration & dosage , Mast-Cell Sarcoma/genetics , Mice , Mice, Inbred DBA , Neoplasm Transplantation , RNA, Messenger/biosynthesis , Receptors, Antigen, T-Cell, alpha-beta/genetics , T-Lymphocytes, Cytotoxic/metabolismABSTRACT
We investigated the efficacy of a recombinant adenovirus in inducing a cytolytic T-lymphocyte (CTL) response in mice against tumor antigen P815A, which is present on mouse mastocytoma P815. The recombinant adenoviral vector (Adeno.PIA) contained the sequence coding for the antigenic nonapeptide which binds to the H-2.Ld molecule to form antigen P815A. We verified that murine cells infected in vitro with Adeno. PIA were lysed by an anti-P815A CTL clone. Mice then received a single intradermal injection of Adeno. PIA, and after a few weeks their spleen cells were stimulated in vitro with tumor cells expressing antigen P815A. An anti-P815A CTL response was observed with the spleen lymphocytes of nearly all the mice, providing the lymphocytes were re-stimulated in vitro with cells expressing both P815A and co-stimulatory molecule B7.1. When the stimulatory cells did not express B7.1, a specific CTL response was observed in only 45% of the mice, and it was less intense. The Adeno. P1A viral vector was unable to raise an anti-P815A response in mice that had been previously infected with a recombinant adenovirus carrying the beta-galactosidase gene or with a defective adenovirus. We conclude that adenoviral vectors may be very useful for the priming of cytolytic T-cell responses directed against human tumor antigens. Other modes of immunization may be necessary to boost the responses induced with adenoviral vectors.
Subject(s)
Adenoviridae/genetics , Antigens, Neoplasm/immunology , T-Lymphocytes, Cytotoxic/immunology , Adenoviridae/immunology , Amino Acid Sequence , Animals , Antigens, Neoplasm/chemistry , Antigens, Neoplasm/genetics , Base Sequence , Female , Genetic Vectors , Humans , Immunization , Mast-Cell Sarcoma/immunology , Mice , Mice, Inbred DBA , Molecular Sequence Data , Recombinant ProteinsABSTRACT
Modification of tumor cells using gene transfer either to enhance host immunity or to act directly on tumor cells is being intensively studied in animal models. Remarkable results have yielded to approved clinical protocols in the treatment of cancer patients using this approach. Several methods of gene delivery have been developed. This article is particularly devoted to the interest of the use of adenoviral vectors in the different strategies of cancer gene therapy.
Subject(s)
Adenoviridae/genetics , Genetic Therapy/methods , Genetic Vectors , Neoplasms/therapy , Animals , Clinical Trials as Topic , Feasibility Studies , Humans , Immunotherapy/methods , Interleukin-2/genetics , Interleukin-2/therapeutic use , MiceABSTRACT
Numerous studies have shown that the expression of immuno-stimulatory genes in tumor cells can result in the development of antitumoral immunity resulting in the rejection of the tumor cells. We show here that the simple integration and expression of the lacZ gene in the highly tumorigenic murine mastocytoma cell line P815 strongly reduces the cell's tumorigenicity. All the animals having rejected P815-lacZ challenges develop a long-lasting immunity against unmodified P815 cells with all of the animals rejecting further challenges with tumorigenic doses of P815 cells. However, this protective immunity conferred by P815-lacZ, directed against both the nuclearly expressed lacZ and surface tumor antigens, is not sufficient to act as curative immunity. In this immunogenic tumor model the expression of the lacZ antigen is more efficient than the irradiation of the cells to induce a strong immune response and an antitumoral state of vaccination in syngeneic animals.
Subject(s)
Gene Transfer Techniques , Lac Operon , Mast-Cell Sarcoma/immunology , Mast-Cell Sarcoma/pathology , Animals , Cytotoxicity, Immunologic/genetics , Mice , Mice, Inbred DBA , Tumor Cells, CulturedABSTRACT
As a first step to evaluate the possibility of gene therapy using adenoviral vectors in hematological malignancies in vivo, we tested the efficacy of gene transfer by a recombinant adenovirus in cell lines and fresh cells from various hematological neoplasms. Thirteen cell lines and samples from 27 patients were studied. Cells were infected by a recombinant adenovirus expressing beta galactosidase gene (Ad RSV betagal) and efficacy of transduction assessed by evaluating betagal expression in cells with a histochemical method. After infection of the cells at a multiplicity of infection (MOI) of 200 p.f.u./cell, the percentage of beta gal-positive cells after 48h was high in two cell lines. K562 (64%) and RPMI 8226 (a myeloma cell line, 65%), relatively large in the two myeloma cell lines tested (41% and 20%, respectively) and in MT4 (an adult T cell leukemia cell line, 38%) and low or absent in other cell lines. In fresh samples from AML, ALL, CLL, NHL, myeloma and MDS, no betagal positive cells were seen 48h and 72h after infection, except in one case of myeloma and one case of CLL (where 10% and 2% of betagal positive cells were seen after infection, respectively). Exposure of fresh malignant cells to GM-CSF before and during adenoviral infection, in three cases, did not increase the number of transfected cells. This suggests that adenoviral vectors, at least in their present form, cannot efficiently be used for direct gene transfer in hematological malignant cells.
Subject(s)
Adenoviruses, Human/genetics , Leukemia/genetics , Lymphoma, Non-Hodgkin/genetics , Transfection , Adenoviruses, Human/enzymology , Adult , Genetic Vectors , Humans , Leukemia/enzymology , Lymphoma, Non-Hodgkin/enzymology , Multiple Myeloma/enzymology , Multiple Myeloma/genetics , Myelodysplastic Syndromes/enzymology , Myelodysplastic Syndromes/genetics , Recombination, Genetic , Tumor Cells, Cultured , beta-Galactosidase/geneticsABSTRACT
The immune response against cells infected by gene therapy vectors may be a major hindrance for gene therapy, destroying infected cells thus limiting the length of exogene expression and quickly eliminating infected cells on repeat administration. Adenoviruses and many other pathogens have evolved strategies for escape from immune surveillance, including the gp19k gene, found in the adenovirus E3 region, known to down-regulate major histocompatibility complex class 1 expression on the cell surface, and thus reduce lysis of the infected cells by cytotoxic T cells. We have constructed an adenoviral vector expressing the genes for beta-galactosidase and gp19k both under the control of constitutive promoters, and compared the capacity of lymphocytes from DBA/2 mice previously injected with the virus or with Ad-beta gal, a virus expressing beta-galactosidase but not gp19k, to lyse target cells infected with various viruses. Lymphocytes raised against Ad-beta gal fail to lyse target cells infected with Ad-beta gal-gp19k significantly, whereas Ad-beta gal infected target cells and a beta-galactosidase expressing cell line are strongly lysed. The administration of Ad-beta gal-gp19k fails to stimulate the proliferation of anti-vector lymphocytes, and thus these lymphocytes show poor cytotoxic activity against Ad-beta gal or Ad-beta gal-gp19k infected cells.
Subject(s)
Adenoviridae/genetics , Adenovirus E1 Proteins/genetics , Adenovirus E3 Proteins/genetics , Genetic Vectors , T-Lymphocytes, Cytotoxic/immunology , 3T3 Cells , Adenoviridae/immunology , Adenoviridae/metabolism , Adenovirus E1 Proteins/immunology , Adenovirus E1 Proteins/metabolism , Adenovirus E3 Proteins/immunology , Adenovirus E3 Proteins/metabolism , Animals , Cells, Cultured , Down-Regulation/immunology , Gene Expression Regulation, Viral , Mice , Mice, Inbred BALB C , Mice, Inbred DBA , RNA/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/immunology , Recombinant Proteins/metabolism , Spleen/immunology , Spleen/metabolism , beta-Galactosidase/genetics , beta-Galactosidase/immunology , beta-Galactosidase/metabolismABSTRACT
Clonal analysis has shown that the SW613-S human colon-carcinoma cell line is heterogeneous: some cell clones display a high level of amplification of the c-myc gene and are tumorigenic in nude mice, whereas others have a small number of copies of this gene and are non-tumorigenic. Tumorigenic clones can proliferate in a chemically defined serum-free medium, whereas non-tumorigenic clones cannot. Suramin, like anti-insulin-like growth factor (IGF) or anti-IGF-I receptor antibodies, efficiently inhibits the growth of tumorigenic clones in defined medium. Inhibition by suramin or by anti-IGF antibodies can be reversed by pure IGF-I or IGF-2. Pure IGF-1 or IGF-2 or culture medium conditioned by tumorigenic clones can stimulate DNA synthesis in cells of non-tumorigenic clones. Co-culture with cells of tumorigenic clones sustains the growth of non-tumorigenic clones in defined medium. Cells of both tumorigenic and non-tumorigenic clones express high-affinity IGF-1 receptors at their surface but tumorigenic clones produce on average 5 times more IGF-1 and 25 times more IGF-2 than non-tumorigenic ones. These results indicate that autocrine growth stimulation of tumorigenic clones by IGFs through the IGF-1 receptor is essential for their ability to grow in defined medium. Since cells of tumorigenic clones produce IGF-2 at levels 80 times higher than IGF-1 and since an antibody strictly specific for IGF-1 has no effect on DNA synthesis in cells of tumorigenic clones grown in defined medium, IGF-2 is very likely the main effector in the autocrine loop.